903 related articles for article (PubMed ID: 27171498)
21. MicroRNA-204 inhibits the proliferation and metastasis of breast cancer cells by targeting PI3K/AKT pathway.
Fan X; Fang X; Liu G; Xiong Q; Li Z; Zhou W
J BUON; 2019; 24(3):1054-1059. PubMed ID: 31424660
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
23. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
Chen M; Zhang H; Zhang G; Zhong A; Ma Q; Kai J; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):74-82. PubMed ID: 30454896
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
Wu YR; Qi HJ; Deng DF; Luo YY; Yang SL
Tumour Biol; 2016 Sep; 37(9):12061-12070. PubMed ID: 27188433
[TBL] [Abstract][Full Text] [Related]
25. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
26. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
27. The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling.
Catanzaro G; Besharat ZM; Miele E; Chiacchiarini M; Po A; Carai A; Marras CE; Antonelli M; Badiali M; Raso A; Mascelli S; Schrimpf D; Stichel D; Tartaglia M; Capper D; von Deimling A; Giangaspero F; Mastronuzzi A; Locatelli F; Ferretti E
Neuropathol Appl Neurobiol; 2018 Dec; 44(7):687-706. PubMed ID: 29478280
[TBL] [Abstract][Full Text] [Related]
28. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.
Matà R; Palladino C; Nicolosi ML; Lo Presti AR; Malaguarnera R; Ragusa M; Sciortino D; Morrione A; Maggiolini M; Vella V; Belfiore A
Oncotarget; 2016 Feb; 7(7):7683-700. PubMed ID: 26655502
[TBL] [Abstract][Full Text] [Related]
29. MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway.
Zhu WJ; Chen X; Wang YW; Liu HT; Ma RR; Gao P
Oncotarget; 2017 Oct; 8(52):89631-89642. PubMed ID: 29163776
[TBL] [Abstract][Full Text] [Related]
30. A miR-567-PIK3AP1-PI3K/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer.
Zhang F; Li K; Yao X; Wang H; Li W; Wu J; Li M; Zhou R; Xu L; Zhao L
EBioMedicine; 2019 Jun; 44():311-321. PubMed ID: 31078520
[TBL] [Abstract][Full Text] [Related]
31. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
32. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
33. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
34. MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway.
Zhu M; Wang X; Gu Y; Wang F; Li L; Qiu X
Arch Biochem Biophys; 2019 Jan; 661():22-30. PubMed ID: 30389444
[TBL] [Abstract][Full Text] [Related]
35. Thidiazuron suppresses breast cancer via targeting miR-132 and dysregulation of the PI3K-Akt signaling pathway mediated by the miR-202-5p-PTEN axis.
Ibrahim HM; Ismail MB; Ammar RB; Ahmed EA
Biochem Cell Biol; 2021 Jun; 99(3):374-384. PubMed ID: 33103467
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
[TBL] [Abstract][Full Text] [Related]
37. MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway.
Gui F; Hong Z; You Z; Wu H; Zhang Y
Cell Biol Int; 2016 Dec; 40(12):1294-1302. PubMed ID: 27600360
[TBL] [Abstract][Full Text] [Related]
38. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer.
Liu MM; Li Z; Han XD; Shi JH; Tu DY; Song W; Zhang J; Qiu XL; Ren Y; Zhen LL
Sci Rep; 2017 Nov; 7(1):15929. PubMed ID: 29162879
[TBL] [Abstract][Full Text] [Related]
39. SOX9/miR-203a axis drives PI3K/AKT signaling to promote esophageal cancer progression.
Wang L; Zhang Z; Yu X; Li Q; Wang Q; Chang A; Huang X; Han X; Song Y; Hu J; Pang L; Hou J; Li F
Cancer Lett; 2020 Jan; 468():14-26. PubMed ID: 31600529
[TBL] [Abstract][Full Text] [Related]
40. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
